Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567319 | 1.00 | RXFP1 (0.51) | RXFP1CA1CA2CA9ALDH1A1 | |
| SCHEMBL2952459 | 0.97 | RXFP1 (0.51) | RXFP1CA1CA2CA9ALDH1A1 | |
| SCHEMBL9797400 | 0.83 | ALDH1A1 (0.48) | RXFP1CA1CA2CA9ALDH1A1 | |
| SCHEMBL13732107 | 0.82 | ALDH1A1 (0.48) | RXFP1CA1CA2CA9ALDH1A1 | |
| SCHEMBL21646755 | 0.82 | USP2 (0.45) | CA1CA2CA9ALDH1A1MAPT | |
| SCHEMBL11561836 | 0.81 | POLB (0.49) | RXFP1CA1CA2CA9ALDH1A1 | |
| SCHEMBL25237122 | 0.79 | HDAC1 (0.44) | RXFP1CA1CA2CA9ALDH1A1 | |
| SCHEMBL13731847 | 0.79 | NISCH (0.47) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL25906721 | 0.79 | CA1 (0.43) | RXFP1CA1CA2CA9ALDH1A1 | |
| SCHEMBL30416876 | 0.79 | HDAC1 (0.44) | RXFP1CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| CN-117209447-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117143042-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| US-20140045910-A1 | NOVEL AMINO-PYRROLINE DERIVATIVES, AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME | UNIVERSITE DE STRASBOURG (FR) | 2014-02-13 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012143660-A1 | NOVEL AMINO-PYRROLINE DERIVATIVES, AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME | UNIVERSITE DE STRASBOURG (FR) | 2012-10-26 | — | — | WO | disclosed |
| EP-1259495-B1 | INDANE DERIVATIVES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LTD (GB) | 2004-09-22 | — | — | EP | disclosed |
| US-6762199-B2 | ABILITY TO MODULATE THE INTERACTION OF THE LIGAND VCAM-1 WITH ITS INTEGRIN RECEPTOR ALPHA 4 BETA 1; TREATMENT OF INFLAMMATION, ATHEROSCLEROSIS, AUTOIMMUNE DISEASE | AVENTIS PHARMA LIMITED (GB) | 2004-07-13 | — | — | US | disclosed |
| US-20030199564-A1 | Indane derivatives | AVENTIS PHARMA LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
| EP-1259495-A2 | INDANE DERIVATIVES AND THEIR USE AS CELL ADHESION INHIBITORS | Aventis Pharma Limited (GB) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064659-A2 | INDANE DERIVATIVES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | DPP4, DPP3, DPP9 | RXFP1 991/4885CA1 915/4885CA2 524/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | RXFP1 235/4885CA1 1975/4885CA2 783/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | RXFP1 4130/4885CA1 4628/4885CA2 4262/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | RXFP1 1067/4885CA1 3665/4885CA2 1245/4885 |
| US-20030199564-A1 | Indane derivatives | ITGA1, ITGB1, VCAM1 | RXFP1 435/4885CA1 2937/4885CA2 2373/4885 |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | RXFP1 1067/4885CA1 3665/4885CA2 1245/4885 |
| US-20140045910-A1 | NOVEL AMINO-PYRROLINE DERIVATIVES, AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME | PYCR1, GLS2, ABAT | RXFP1 410/4885CA1 4735/4885CA2 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.